Barclays
LXEO icon

Barclays’s Lexeo Therapeutics LXEO Stock Holding History

Barclays’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.7K Buy
16,257
+4,092
+34% +$22.1K ﹤0.01% 4167
2026
Q1 		$69.8K Sell
12,165
-176,589
-94% -$1.25M ﹤0.01% 4180
2025
Q4 		$1.87M Buy
188,754
+77,175
+69% +$704K ﹤0.01% 2981
2025
Q3 		$741K Sell
111,579
-4,563
-4% -$22.1K ﹤0.01% 3553
2025
Q2 		$467K Buy
116,142
+69,475
+149% +$228K ﹤0.01% 3792
2025
Q1 		$162K Sell
46,667
-8,494
-15% -$37.6K ﹤0.01% 4159
2024
Q4 		$363K Buy
55,161
+4,951
+10% +$39K ﹤0.01% 4017
2024
Q3 		$454K Buy
50,210
+31,057
+162% +$370K ﹤0.01% 3842
2024
Q2 		$307K Sell
19,153
-3,776
-16% -$54.8K ﹤0.01% 3333
2024
Q1 		$360K Buy
22,929
+7,412
+48% +$116K ﹤0.01% 3788
2023
Q4 		$208K Buy
+15,517
New +$193K ﹤0.01% 4401

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Barclays's LXEO Position: Q2 2026 in Review

Barclays increased its Lexeo Therapeutics (LXEO) stake by 34% in Q2 2026, buying an estimated $22.1K and bringing the position to 16,257 shares worth $75.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Barclays first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.87M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Barclays held 16,257 shares of Lexeo Therapeutics worth $75.7K as of Q2 2026.
  • Barclays bought 4,092 Lexeo Therapeutics shares in Q2 2026, an estimated $22.1K.
  • Lexeo Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4167 holding.
  • Barclays first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Barclays's Lexeo Therapeutics position peaked at $1.87M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.